VEGFR2 antibody

Synonyms:CD309 antibody, Fetal liver kinase 1 antibody, FLK 1 antibody, FLK1 antibody, KDR antibody, Kinase insert domain receptor antibody, VEGF Receptor 2 antibody, VEGFR antibody, VEGFR 2 antibody, VEGFR2 antibody
Catalogue No.:FNab09795Reactivity:Human, Mouse, Rat
Host:RabbitTested Application:ELISA, IHC, WB,FC
Clonality:polyclonalIsotype:IgG
  • SPECIFICATIONS
  • CITATIONS
Product Name
VEGFR2 antibody
Catalogue No.
FNab09795
Size
100μg
Form
liquid
Purification
Immunogen affinity purified
Purity
≥95% as determined by SDS-PAGE
Clonality
polyclonal
Isotype
IgG
Storage
PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
Immunogen
Immunogen
Vascular endothelial growth factor receptor 2
Alternative Names
CD309 antibody, Fetal liver kinase 1 antibody, FLK 1 antibody, FLK1 antibody, KDR antibody, Kinase insert domain receptor antibody, VEGF Receptor 2 antibody, VEGFR antibody, VEGFR 2 antibody, VEGFR2 antibody
UniProt ID
P35968
Observed MW
200 kDa
Application
Tested Applications
ELISA, IHC, WB,FC
Recommended dilution
WB: 1:500-1:1000; IHC: 1:50-1:500
Validated Images
human placenta tissue were subjected to SDS PAGE followed by western blot with FNab09795(VEGFR2 Antibody) at dilution of 1:600
Immunohistochemistry of paraffin-embedded human lung cancer tissue slide using FNab09795(VEGFR2 antibody) at dilution of 1:200
Background
KDR, also named as VEGFR-2, FLK1 and CD309, is a receptor for VEGF or VEGFC. KDR which belongs to the protein kinase superfamily, has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. KDR functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. Mutations of this gene are implicated in infantile capillary hemangiomas.
IF: 11.467
Journal:
Journal of Controlled Release
Author:
State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, China
Cited Date:
2023-06-16
Product: